VLS Valneva SE

VALNEVA: Declaration of shares and voting rights - January 31, 2024

VALNEVA: Declaration of shares and voting rights - January 31, 2024

VALNEVA

Declaration of shares and voting rights

January 31, 2024

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: February 7, 2024

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



138,912,142



ordinary shares with a par value of €0.15 each
161,866,457 



Double voting rights granted on 197,236 ordinary shares



 



Transfer into bearer form of 500,000 shares with double voting rights



 



Sale of 20,000 shares with double voting rights



 



Transfer into bearer form of 100 shares with double voting rights



 
Between January 3 & January 24, 2024

   



January 8, 2024



 



  January 10, 2024

   



January 23, 2024



 
161,742,135

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.



Attachment



EN
07/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Martial Descoutures
  • Martial Descoutures
Damien Choplain ... (+2)
  • Damien Choplain
  • Oscar Haffen Lamm

Valneva : Strong H1 - Key Lyme vaccine catalyst ahead in Q4

Valneva delivered a solid H1 and reaffirmed its 2025 guidance. The company’s cash position, standing at €161m, is sufficient to fund operations through 2027e, providing solid financial visibility. Looking ahead, the next key catalyst is the Phase III data readout for VLA15, Valneva’s Lyme disease v

Martial Descoutures
  • Martial Descoutures

ResearchPool Subscriptions

Get the most out of your insights

Get in touch